Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
Wai-Tong NgCheuk-Wai ChoiBarton ButRoger K-C NganStewart TungAshley C ChengDora Lai Wan KwongTai-Xiang LuAnthony T C ChanHarry YiuSarah LeeFrank WongKam-Tong YuenRichard J ChappellAnne Wing-Mui LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Both concurrent and IC/AC are needed for locoregionally advanced NPC, even for patients irradiated by IMRT; the concurrent platinum dosage could be set at ≥160 mg/m2 when coupled with adequate induction/adjuvant dosage at ≥260 mg/m2 (or at least ≥240 mg/m2). To achieve these optimal dosages, IC-CRT at conventional fractionation is favored.
Keyphrases